A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body

NCT06492135 · Completed

Last updated 2026-05-28

This study is testing how different doses of the drug survodutide are absorbed in the body of Chinese adults who are overweight or have obesity.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 30 people

Who can join Ages 18–60 · all sexes Healthy volunteers accepted.

Timeline Started 2024-08 · est. completion 2025-04

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06492135 ↗

Description as written by the study sponsor.

This study is open to Chinese adults aged 18 to 60 with overweight or obesity. People can join the study if they have a Body Mass Index from 24 to 40.0 kg/m2. Survodutide is a medicine being developed to help people with overweight or obesity. The purpose of this study is to find out how different doses of survodutide are taken up in the body. Other goals are to test if participants can tolerate different doses of survodutide and whether survodutide helps people with overweight or obesity. Participants receive survodutide as an injection under the skin once a week for 7.5 months. During this time, participants visit the study site 33 times. 4 of the visits require a stay in the hospital. At the visits, doctors take blood samples to measure the levels of survodutide in participants' blood. The doctors also check participants' health and take note of any unwanted effects.

Treatments tested

survodutide Drug

survodutide

Main thing measured	AUC0-168 (area under the concentration-time curve of survodutide in plasma over the time interval from 0 to 168h)
Sponsor	Boehringer Ingelheim
Conditions studied	Overweight, Obesity
GLP-1 drugs	survodutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06492135 ↗